With the rise in incidence of differentiated thyroid cancer and its favorable prognosis, tools that effectively identify individuals at heightened risk of recurrence have become increasingly imperative. Initially, the American Thyroid Association recommended the Initial Risk Stratification System to estimate such risks; however, this measure was unable to account for the individual patient’s response to treatment. Thus, dynamic risk stratification (DRS) was introduced in 2010 as a measure that could be continually modified based on new data gathered at each follow-up visit. Although it was initially conceived for adults who underwent total thyroidectomy with adjuvant radioactive iodine ablation (RAI), the principles of DRS have been validated in patients who have undergone any thyroid surgery (total thyroidectomy or thyroid lobectomy) with or without RAI as well as in the pediatric population. More recent work assessing the efficacy of DRS has attempted to incorporate molecular marker data in designing such risk models.